Sunshine Biopharma, Inc.
6100 Royalmount Avenue
Montreal
Quebec
H4P 2R2
Canada
Tel: 514-496-5197
Fax: 450-689-639
Website: http://sunshinebiopharma.com/
Email: info@sunshinebiopharma.com
122 articles about Sunshine Biopharma, Inc.
-
Sunshine Biopharma Completes the Synthesis of Four Potential Inhibitors of Coronavirus Protease
8/25/2020
Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has completed the synthesis of four different potential inhibitors of Coronavirus protease.
-
Sunshine Biopharma, Inc. Signs Licensing Agreement For Three Additional Generic Products For Treatment Of Cancer And BPH
6/30/2016
-
Sunshine Biopharma, Inc. Signs Licensing Agreement For Anastrozole, The Company's First Generic Drug For Treatment Of Breast Cancer
5/12/2016
-
Sunshine Biopharma, Inc. Eliminates The Debt Obligations Associated With The Recently Acquired Patents For Its Adva-27a Anticancer Compound
3/16/2016
-
Sunshine Biopharma, Inc. Is Moving Forward With Its Development Plans For Adva-27a Anticancer Compound
1/20/2016
-
Sunshine Biopharma, Inc. Acquires All Remaining Worldwide Patents For Its Adva-27a Anticancer Compound
12/28/2015
-
Sunshine Biopharma, Inc. Acquires The U.S. Patent For Its Anticancer Compound, Adva-27a
10/13/2015
-
Sunshine Biopharma, Inc. Announces That The Initial Manufacturing Sample Of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving The Way For Clinical Trials
8/4/2015
-
Sunshine Biopharma, Inc. To Receive This Week A Sample From The Adva-27a Manufacturing Currently Underway At Lonza Inc. In Switzerland
5/27/2015
-
Sunshine Biopharma, Inc. Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In India
3/24/2015
-
Sunshine Biopharma, Inc. Announces Change To Its Board Of Directors And Officers
2/26/2015
-
Sunshine Biopharma, Inc. Signs Agreement With Lonza Biologics Inc. To Manufacture Its Lead Anti-Cancer Compound, Adva-27a
11/20/2014
-
Sunshine Biopharma, Inc. Retains Renmark Financial Communications To Provide Investor Relations
10/17/2014
-
Sunshine Biopharma, Inc. Retains Renmark Financial Communications To Provide Investor Relations
10/14/2014
-
Sunshine Biopharma, Inc.'s Wholly Owned Canadian Subsidiary Completes The SOP's Required By Health Canada To Secure Drug Establishment License
10/3/2014
-
Sunshine Biopharma, Inc. Negotiating With CRO's To Initiate Master Drug File For Adva-27a Anticancer Compound
9/4/2014
-
Sunshine Biopharma, Inc. Launches Sunshine Biopharma Canada Inc., A Wholly Owned Canadian Subsidiary In Anticipation Of Signing Manufacturing And Commercialization Contracts In Canada
7/29/2014
-
Sunshine Biopharma, Inc.'s Adva-27a Featured In 2014 Worldwide Uterine Cancer Report For Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
6/10/2014
-
Sunshine Biopharma, Inc. Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In Canada
5/12/2014
-
Sunshine Biopharma, Inc. Secures Funding For Its Adva-27a Anticancer Compound From Dutchess Opportunity Fund II
4/29/2014